Jefferies raises Certara stock price target to $12 on software growth
Jefferies raised its price target for Certara (CERT) to $12.00, citing improved software growth and organic bookings acceleration. The stock has risen 95% in six months, exceeding the new target. Certara reported Q3 2026 revenue of $94.9 million, up 2.81% from estimates, with software sales increasing 11%. UBS also raised its target to $13.00, noting strong biopharma demand.
How this was made
The 30-second read
Why it matters
Analyst upgrades provide fresh guidance but limited upside as the market price exceeds the new target.
Market read
The article offers a new analyst price target for Certara, which may influence short‑term trading but has modest broader market impact.
What to watch
Upcoming earnings or guidance could override the analyst's price target impact.
Background
Jefferies and UBS both raised price targets for Certara, citing accelerating software bookings and revenue growth.
Ticker impact
Jefferies raised its price target on Certara to $12 from $7.45 and maintained a Hold rating, marking a fresh analyst upgrade.
modest downside pressure as traders may book gains after the upgrade.
Target raise is new information, but the market price already exceeds the level, limiting upside.
Market effects
The upgrade may lift sentiment toward the biotech software sector, but impact is limited.
U.S. market focus; no broader regional effect.
Low; relevance confined to Certara and its niche.
Counterpoint
With the stock already above the new target, the upgrade could be a false signal and trigger a pullback.
Key entities
- companyCertara Inc.
Provider of drug development software and services.
- analystJefferies
Investment bank that raised the price target.




